H. Lundbeck A/S and Takeda Pharmaceutical Company Limited today announced the decision to investigate Lu AA24530 for the treatment of depression in patients. Based on positive, pre-clinical results, as well as the positive conclusion of the phase I trials in healthy individuals, the first patient in a 600 patient phase II study has been enrolled. Lu AA24530, discovered by Lundbeck, belongs to a new chemical class and represents an approach that is markedly different to any currently marketed antidepressants. Lu AA24530 is being jointly developed by Lundbeck and Takeda and is the second most advanced compound in the collaboration on a new class of compounds to treat mood and anxiety disorders."Lu AA24530 is an outcome of efforts to design and develop novel psychotropics displaying clear-cut improvements in efficacy without compromising patient tolerability and compliance," said Anders Gersel Pedersen, head of Development at Lundbeck. In September 2007, Lundbeck and Takeda formed an alliance to develop and commercialize a portfolio of novel compounds in the US and Japan for the treatment of mood and anxiety disorders, including Lu AA24530 and Lu AA21004, which is in a more advanced clinical development stage."We are very pleased with the progression of development stage of Lu AA24530, which is one of the compounds covered by our alliance with Lundbeck," says Masaomi Miyamoto, General Manager of Pharmaceutical Development Division of Takeda. "We will collaborate closely with Lundbeck in the next clinical stage." The content of this release will have no influence on the Lundbeck Group's financial result for 2007. Takeda contact Investors & Media: Seizo Masuda Coordinator, Corporate Communications Dept. +81-3-3278-2037 Lundbeck contacts Investors: Media: Jacob Tolstrup Caroline Broge Director, Investor Relations Media Relations Manager +45 36 43 30 79 +45 36 43 26 38 ________________________ Stock Exchange Release No 300 - 24 October 2007 About Takeda Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, www.takeda.com. About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com.
Lu AA24530 for the treatment of mood and anxiety disorders enters into clinical phase II
| Source: H. Lundbeck A/S